drugset
drugset / Trial / NCT00111696

Study of the Tumor Saturation and Biological Activity of MEDI-522 (Abergrin) in Patients With Advanced Malignant Melanoma

NCT00111696 ↗

Phase 1 Completed 18 enrolled MedImmune LLC
Non-randomizedSingle-groupOpen-labelTreatment

Summary

To describe the tumor tissue saturation by MEDI-522 in patients with advanced malignant melanoma.

Timeline

Start
2005-05
Primary completion
2007-08
Completion
2007-11

Drugs

EvaluationDrugModalityDoseRoute
Subject etaracizumab Monoclonal antibody — —

Indications

melanoma